CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present data on the company’s first-in-human clinical study in Parkinson’s disease at Neuroscience 2016.
Session Information
Type: Nanosymposium
Title: Transplants and Other Treatments of Parkinson's Disease
Date: November 14, 2016
Time: 8:00 AM
Location: SDCC 1B, San Diego Convention Center
About the clinical study
The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranialy transplanted into patients with moderate to severe Parkinson's disease (ClinicalTrials.gov Identifier: NCT02452723). The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC®. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.
The study is underway at The Royal Melbourne Hospital in Australia. The study is being overseen by ISCO subsidiary, Cyto Therapeutics Pty Ltd.
Presentation by Prof R Barker - University of Cambridge: "Can we repair the brain in PD using cell-based therapies?"
Autologous IP Stem Cell Update
A flying SPARK?
